Document registry — page 32
Every document the Institute has published, 1,621 in total, with its identifier, type, certainty rating and review date.
Documents
-
Randomised crossover, phase 1 study of Retatrutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low14 Jan 2024 -
Phase 1 ascending dose, phase 1 study of Semaglutide in obesity and prediabetes over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low12 Jan 2024 -
Phase 1 ascending dose, phase 1 study of Liraglutide in sleep apnoea and obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low11 Jan 2024 -
Dependence on nicotine-containing products, characterised by craving, tolerance and withdrawal.
09 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation randomising 361 participants over 28 days. Primary result: A…
Moderate09 Jan 2024 -
Randomised crossover, phase 1 study of Semaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low09 Jan 2024 -
Phase 1 ascending dose, phase 1 study of GHK-Cu in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low08 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Exenatide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute holds…
Very low08 Jan 2024 -
Observational, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low06 Jan 2024 -
Phase 1 ascending dose, phase 1 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Jan 2024 -
Randomised crossover, phase 1 study of AOD-9604 in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low05 Jan 2024 -
Single-arm open-label, phase 2 study of Liraglutide in mash over open-label extension of the parent trial. The Institute holds no reported primary result for this record…
Very low04 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Glutathione in cognition randomising 45 participants over 3 months. Primary result: No significant…
Low01 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low30 Dec 2023 -
Consultation on the scope and drafting conventions of the analytical and methodological standards series. The central question put was whether an Institute standard…
28 Dec 2023 -
Event-driven cardiovascular outcome trial, phase 3 study of Liraglutide in cardiovascular and type 2 diabetes randomising 9,340 participants over median 3.8 years…
High28 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Semaglutide in hfpef and obesity over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low28 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Pramlintide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low27 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low27 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low27 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Pramlintide in type 2 diabetes randomising 656 participants over 52 weeks. Primary result: A modest…
Moderate24 Dec 2023 -
Randomised crossover, phase 1 study of Exenatide in cardiovascular over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low24 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of Thymosin beta-4 in cardiovascular over as stated in the parent protocol. The Institute holds no reported…
Very low24 Dec 2023 -
Observational, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low24 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low24 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of SS-31 (elamipretide) in mitochondrial disease over as stated in the parent protocol. The Institute holds…
Very low23 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Dulaglutide in cardiovascular and type 2 diabetes over as stated in the parent protocol. The Institute…
Very low23 Dec 2023 -
Record of documents ratified in the 2023 Q4 assessment cycle.
22 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of CagriSema (cagrilintide with semaglutide) in type 2 diabetes and obesity over as stated in the parent…
Very low22 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Kisspeptin-10 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low21 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low21 Dec 2023 -
Randomised crossover, phase 1 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low20 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing randomising 72 participants over 84 days. Primary result: A signal in a…
Low18 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Semaglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low18 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Tirzepatide in type 2 diabetes and cardiovascular over as stated in the parent protocol. The Institute holds no reported primary…
Very low18 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low17 Dec 2023 -
Randomised crossover, phase 1 study of Tirzepatide in obesity and type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result…
Very low17 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low16 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low16 Dec 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Liraglutide in adolescent obesity over as stated in the parent protocol. The Institute holds no reported…
Very low16 Dec 2023
page 32 of 41